Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28291327 | 0.83 | EPHX1 (0.50) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL15447812 | 0.82 | NPSR1 (0.68) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL13450032 | 0.81 | SMN1; SMN2 (0.49) | EPHX1NPSR1POLBKMT2AMEN1 | |
| SCHEMBL14492245 | 0.81 | SMN1; SMN2 (0.49) | EPHX1NPSR1POLBKMT2AMEN1 | |
| SCHEMBL4070701 | 0.80 | EPHX1 (0.55) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL28291418 | 0.80 | GNAI3 (0.44) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL21882064 | 0.79 | EPHX1 (0.53) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL27224567 | 0.78 | EPHX1 (0.57) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL19764243 | 0.78 | GNAI3 (0.49) | EPHX1GNAI3GNAO1GNAI1NPSR1 | |
| SCHEMBL18872267 | 0.77 | GNAI3 (0.48) | EPHX1GNAI3GNAO1GNAI1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022194-B1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-9573957-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| US-9573957-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| WO-2015009611-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2013044360-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
| US-6469172-B2 | 2-AMINO-6-((4-AMINOPIPERIDIN-1-YL)METHYL)PYRIDINE; CHEMICAL INTERMEDIATE FOR MUSCARINIC M3 RECEPTOR ANTAGONISTS; ACYLATION OF 2-AMINO-6-BROMOPYRIDINE WITH TRIMETHYLACETIC ACID | MERCK & CO., INC. | 2002-10-22 | — | — | US | disclosed |
| US-20010051727-A1 | Process for the preparation of chemical compounds | MERCK& CO., INC. | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051727-A1 | Process for the preparation of chemical compounds | CHRM3, CHRM5, CHRM2 | EPHX1 3994/4885GNAI3 1488/4885GNAO1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.